Ibrutinib, an oral irreversible BTK inhibitor, covalently binds the 481 cysteine of the kinase domain, blocking BTK activity but not interactions with Syk, and has been approved in 2016 for treatment of CLL, MCL, and Waldenström’s macroglobulinemia [14]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.